Related Experiment Video

Updated: Apr 21, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

4.5K

Invasive candidiasis and candidaemia in neonates and children: update on current guidelines

Athanasios Tragiannidis1, Christos Tsoulas, Andreas H Groll

  • 1Hematology Oncology Unit, 2nd Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

Mycoses
|October 29, 2014
PubMed

Insights

Invasive candidiasis (IC) and candidaemia remain serious threats to immunocompromised children. This review summarizes international guidelines for managing and preventing these serious fungal infections in pediatric patients.

Area of Science:

  • Medical Mycology
  • Pediatric Infectious Diseases

Background:

  • Invasive candidiasis (IC) and candidaemia are significant causes of illness and death in immunocompromised children and ICU patients.
  • Despite advances, high mortality and economic costs persist for these fungal infections.

Purpose of the Study:

  • To review and synthesize current international guidelines for managing and preventing IC and candidaemia in pediatric populations.
  • To provide a consolidated resource for healthcare professionals treating invasive fungal infections in neonates and children.

Main Methods:

  • Systematic review of guidelines from major international medical societies.
  • Comparative analysis of recommendations for diagnosis, treatment, and prevention of IC/candidaemia in children.

Main Results:

  • Key recommendations from IDSA, ECIAL, ESCMID, and DMS/GMSPG are summarized.
  • Guidelines cover diagnosis, antifungal therapy, and preventative strategies tailored for pediatric patients.

Conclusions:

  • Adherence to updated guidelines is crucial for improving outcomes in pediatric invasive candidiasis and candidaemia.
  • Standardized management approaches can reduce mortality and the burden of these infections in vulnerable children.

Keywords:
Guidelinescandidaemiachildreninvasive candidiasisneonatespreventiontreatment

More Related Videos

Generation of Fluorescent Protein Fusions in Candida Species09:27

Generation of Fluorescent Protein Fusions in Candida Species

Published on: March 4, 2017

10.3K
Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging03:24

Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging

Published on: March 22, 2024

2.2K

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
87
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
395
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
918
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
58
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
5
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
532